@article{f64e3cee1ca342e6836b3652ef381e1e,
title = "Type I insulin-like growth factor receptor signaling in hematological malignancies",
abstract = "The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.",
keywords = "IGF-IR, Leukemia, Lymphoma, Plasma cell myeloma",
author = "Deeksha Vishwamitra and George, {Suraj Konnath} and Ping Shi and Kaseb, {Ahmed O.} and Amin, {Hesham M.}",
note = "Funding Information: We are grateful to Dawn Chalaire for outstanding assistance with the preparation of this paper, and to Jordan Pietz for exceptional help with the preparation of the figures. The authors apologize to the investigators whose contributions to this field could not be discussed or cited because of space limitations. This work is supported by an R01CA151533 grant from the National Cancer Institute (NCI) to H.M.A., an R21CA170035 grant from the NCI to A.O.K., and by grant 14520720700 from Shanghai Scientific and Technological Innovation Project to P.S. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NCI or the National Institutes of Health.",
year = "2017",
doi = "10.18632/oncotarget.12123",
language = "English (US)",
volume = "8",
pages = "1814--1844",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1",
}